BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $417,140 | +81055.6% | 11,053 | -2.1% | 0.02% | -18.5% |
| Q2 2023 | $514 | -66.6% | 11,288 | -70.3% | 0.03% | -67.9% |
| Q1 2023 | $1,540 | -20.9% | 37,960 | -0.6% | 0.08% | -19.2% |
| Q4 2022 | $1,947 | -99.9% | 38,190 | -2.1% | 0.10% | +13.0% |
| Q3 2022 | $2,100,000 | -16.6% | 38,991 | -0.6% | 0.09% | -10.7% |
| Q2 2022 | $2,519,000 | -17.2% | 39,222 | -0.1% | 0.10% | +5.1% |
| Q1 2022 | $3,044,000 | -10.9% | 39,257 | -1.4% | 0.10% | -9.3% |
| Q4 2021 | $3,417,000 | +2.3% | 39,801 | -4.1% | 0.11% | -3.6% |
| Q3 2021 | $3,339,000 | -0.1% | 41,516 | 0.0% | 0.11% | +19.1% |
| Q2 2021 | $3,342,000 | -5.5% | 41,516 | -1.0% | 0.09% | -8.7% |
| Q1 2021 | $3,536,000 | -18.8% | 41,923 | -22.7% | 0.10% | -23.7% |
| Q4 2020 | $4,353,000 | -2.4% | 54,248 | -2.2% | 0.14% | -22.0% |
| Q3 2020 | $4,461,000 | -17.6% | 55,468 | -11.8% | 0.17% | -19.9% |
| Q2 2020 | $5,414,000 | +5.5% | 62,883 | -0.5% | 0.22% | -9.2% |
| Q1 2020 | $5,131,000 | -3.7% | 63,193 | -0.8% | 0.24% | +23.3% |
| Q4 2019 | $5,326,000 | -15.6% | 63,688 | -11.8% | 0.19% | -13.5% |
| Q3 2019 | $6,314,000 | +6.8% | 72,182 | 0.0% | 0.22% | +6.7% |
| Q2 2019 | $5,912,000 | +0.6% | 72,182 | -0.2% | 0.21% | +7.7% |
| Q1 2019 | $5,879,000 | +23.5% | 72,305 | 0.0% | 0.19% | +14.8% |
| Q4 2018 | $4,759,000 | -14.8% | 72,305 | -0.2% | 0.17% | +0.6% |
| Q3 2018 | $5,588,000 | +4.4% | 72,485 | 0.0% | 0.17% | +1.2% |
| Q2 2018 | $5,352,000 | +13.5% | 72,485 | 0.0% | 0.17% | +15.3% |
| Q1 2018 | $4,714,000 | -95.2% | 72,485 | -95.2% | 0.14% | -94.6% |
| Q4 2017 | $98,070,000 | +2.0% | 1,517,179 | -1.0% | 2.69% | +2.8% |
| Q3 2017 | $96,167,000 | +3.4% | 1,532,534 | -0.2% | 2.62% | -5.3% |
| Q2 2017 | $92,961,000 | +14.9% | 1,535,525 | -1.5% | 2.76% | +18.9% |
| Q1 2017 | $80,872,000 | -15.2% | 1,559,436 | -27.5% | 2.32% | -22.1% |
| Q4 2016 | $95,367,000 | -7.1% | 2,150,819 | -0.3% | 2.98% | -3.7% |
| Q3 2016 | $102,692,000 | -5.1% | 2,157,391 | -9.9% | 3.09% | +1.8% |
| Q2 2016 | $108,242,000 | +5.7% | 2,393,665 | -4.0% | 3.04% | +7.8% |
| Q1 2016 | $102,399,000 | +7.6% | 2,492,683 | -0.1% | 2.82% | +0.8% |
| Q4 2015 | $95,210,000 | +16.0% | 2,495,682 | -0.1% | 2.80% | +14.4% |
| Q3 2015 | $82,064,000 | -53.9% | 2,498,141 | -1.8% | 2.44% | -50.3% |
| Q2 2015 | $177,900,000 | +1.3% | 2,543,966 | -0.8% | 4.91% | +3.6% |
| Q1 2015 | $175,690,000 | -6.8% | 2,564,814 | -0.3% | 4.74% | -1.7% |
| Q4 2014 | $188,527,000 | +1.8% | 2,572,339 | -0.3% | 4.83% | +13.2% |
| Q3 2014 | $185,258,000 | -1.1% | 2,581,277 | -0.4% | 4.26% | +6.5% |
| Q2 2014 | $187,413,000 | -2.1% | 2,592,155 | -0.4% | 4.00% | -9.2% |
| Q1 2014 | $191,444,000 | +5.8% | 2,601,848 | -0.0% | 4.41% | +4.8% |
| Q4 2013 | $180,966,000 | +5.8% | 2,601,953 | -0.1% | 4.21% | +2.3% |
| Q3 2013 | $171,049,000 | -5.3% | 2,603,888 | -0.1% | 4.11% | -8.9% |
| Q2 2013 | $180,591,000 | – | 2,607,066 | – | 4.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |